Antigen-specific reactivity in peripheral blood mononuclear cells from patient no. 8 immunized with MUC1-derived peptide-pulsed dendritic cells
| Antigens . | HIV . | M1.1 . | M1.2 . | MAGE . | CEA . |
|---|---|---|---|---|---|
| Before therapy | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| 1. Vaccination | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 |
| 3. Vaccination | 0.1 | 0.8 | 2 | 0.2 | 0.1 |
| 5. Vaccination | 0.2 | 0.7 | 1.6 | 0.1 | 0.2 |
| 6. Vaccination | 0.1 | 0.1 | 1.6 | 0.5 | 0.4 |
| 9. Vaccination | 0.2 | 0.2 | 0.8 | 0.4 | 0.3 |
| Antigens . | HIV . | M1.1 . | M1.2 . | MAGE . | CEA . |
|---|---|---|---|---|---|
| Before therapy | 0.1 | 0.1 | 0.1 | 0.1 | 0.1 |
| 1. Vaccination | 0.2 | 0.2 | 0.1 | 0.1 | 0.1 |
| 3. Vaccination | 0.1 | 0.8 | 2 | 0.2 | 0.1 |
| 5. Vaccination | 0.2 | 0.7 | 1.6 | 0.1 | 0.2 |
| 6. Vaccination | 0.1 | 0.1 | 1.6 | 0.5 | 0.4 |
| 9. Vaccination | 0.2 | 0.2 | 0.8 | 0.4 | 0.3 |
Refer to Table 2 for abbreviations.
PBMNCs from each patient were incubated with autologous PBMNCs pulsed with the indicated peptides for 6 hours and IFN-γ production was assessed by flow cytometry after intracellular staining for IFN-γ in CD8 positive lymphocytes. Numbers represent the percentage of IFN-γ–expressing cells in the lymphocyte gate.